Table 3.
Univariate and multivariate analyses of prognostic factors for overall survival and progression free survival.
| Variable | OS | PFS |
|---|---|---|
| Age (y) (UVA Cox) | 0.20 | 0.76 |
| PRIMARY CANCER (UVA LOG RANK) | ||
| Colorectal, p | 0.71 | 0.31 |
| Lung, head/neck, esophagus, p | 0.28 | 0.49 |
| SITE INVOLVED (UVA LOG RANK) | ||
| Lung, p | 0.97 | 0.66 |
| Thoracic lymph nodes, p | 0.77 | 0.95 |
| Liver, p | 0.85 | 0.39 |
| Oligometastatic lesions treated UVA (Cox), p | 0.77 | 0.91 |
| involved organs (1 vs. 2-3) UVA (Cox), p | 0.53 | 0.77 |
| History of >5 metastases prior to enrollment (UVA Cox) | 0.35 | 0.59 |
| Systemic therapy for metastasis (UVA Cox) | 0.20 | 0.25 |
| BED 75 Gy or greater (UVA Cox) | 0.10 | 0.14 |
| History of prior curative local treatment (UVA Cox) | 0.81 | 0.65 |
| SUM OF GTV (CM3) | ||
| UVA (Cox), p | <0.01 | 0.01 |
| UVA HR (95% CI) per 10 cm3 | 1.04 (1.014–1.075) | 1.04 (1.009–1.07) |
| MVA (Cox), p | <0.01 | 0.03 |
| MVA HR (95% CI) per 10 cm3 | 1.05 (1.014–1.099) | 1.04 (1.005–1.09) |